Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide Dosage and Weight Loss Guide PEP DOSE